Coronavirus Drugs Already in the Pipeline
It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.
What drugs will be available to treat COVID-19? Here's a quick rundown and a timeline for when to expect them. Note that these drugs have not been proven yet in trials of patients suffering from the novel coronavirus, and as such do not have official FDA approval, but they may still be helpful.
A lot of attention has been paid to existing antimalarials (in the chloroquine family) or flu drugs (favipiravir)
The antimalarials are in short supply, but production is ramping up. Mylan (MYL) and Teva Pharmaceuticals (TEVA) plan to jump-start production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets tablets through wholesalers to hospitals by March 31. We expect them to be widely available in mid-April.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.
One side effect of COVID-19 is a so-called "cytokine storm," in which the virus causes the immune system to overreact. Actemra by Roche (RHHBY) and Kevzara, by Sanofi (SNY) and Regeneron (REGN), are existing arthritis drugs which may also be able to counter a cytokine storm. Currently available, but starting testing for COVID-19 use.
Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away.
Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall. Companies working on this idea: Regeneron, Eli Lilly (LLY) with AbCellera, Vir Biotechnology (VIR), and Biogen (BIIB).
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
David is both staff economist and reporter for The Kiplinger Letter, overseeing Kiplinger forecasts for the U.S. and world economies. Previously, he was senior principal economist in the Center for Forecasting and Modeling at IHS/GlobalInsight, and an economist in the Chief Economist's Office of the U.S. Department of Commerce. David has co-written weekly reports on economic conditions since 1992, and has forecasted GDP and its components since 1995, beating the Blue Chip Indicators forecasts two-thirds of the time. David is a Certified Business Economist as recognized by the National Association for Business Economics. He has two master's degrees and is ABD in economics from the University of North Carolina at Chapel Hill.
-
Visa Is the Worst Dow Stock Wednesday. Here's Why
Visa stock is down sharply Wednesday after the credit card company came up short of revenue expectations for its fiscal Q3.
By Joey Solitro Published
-
Another Analyst Moves to the Sidelines on Tesla Stock After Earnings
Tesla stock is spiraling Wednesday after the EV maker's big earnings miss and Wall Street has been quick to weigh in. Here's what you need to know.
By Joey Solitro Published
-
Kiplinger Special: The Long-Term Future of the U.S. Economy
The Kiplinger Letter Kiplinger's report into what it will take the U.S. to maintain a healthy economic growth rate.
By David Payne Published
-
Fed Rate Cuts Still on Hold
The Kiplinger Letter With inflation stubbornly elevated, the Federal Reserve will keep interest rates high for now.
By David Payne Published
-
A Spotlight on the Pacific States: The Kiplinger Letter
The Kiplinger Letter Most Pacific states are seeing good job growth in multiple sectors including tourism, hospitality, and construction.
By David Payne Published
-
The Robots Are Coming... But Not For a While
The Kiplinger Letter There’s excitement in the tech sector over the potential of humanoid robots, but widespread adoption is likely to be years away.
By John Miley Published
-
Farmers Face Another Tough Year As Costs Continue to Climb: The Kiplinger Letter
The Kiplinger Letter Farm income is expected to decline for a second year, while costs continue to up-end farm profitability.
By Matthew Housiaux Published
-
A Spotlight on the Mountain States: The Kiplinger Letter
The Kiplinger Letter Most Mountain states are seeing good job growth in multiple sectors from healthcare, energy, and semiconductor production to farming and government.
By David Payne Last updated
-
A Spotlight on the Plains States: The Kiplinger Letter
The Kiplinger Letter The labor market is tight in the Plains states and outside of healthcare and construction most sectors are flat or down.
By David Payne Published
-
Kiplinger's Commodities Forecast
The Kiplinger Letter Following a rocky few years for markets, we expect commodities to be less volatile in 2024, as a post-pandemic normal finally emerges.
By Matthew Housiaux Published